When time is of essence and every moment counts, Southern Tier Cancer Care is here….
We realize that you are apprehensive and fearful. By providing professional assistance through education, the latest approved treatments available and most importantly, compassionate care, we are dedicated to guiding patients to hope, help, and healing.
Southern Tier Cancer Care Team is Committed to
Excellence in Providing Comprehensive, Up to date,
Compassionate and Quality care for Cancer Patients.
Please proceed immediately to the nearest emergency room for any medical emergencies especially fever greater than or equal to 100.4 while on chemotherapy.
If you need to reach Dr Soni immediately for problems related to cancer or chemotherapy,Please call the answering service at (716) 559 1105.
Please call your primary physician or emergency room at Olean General Hospital at (716) 375 4149 for any urgent concerns after office hours or if Dr Soni is away.
High-dose interferon (IFN) for 1 year (HDI) is the US Food and Drug Administration–approved adjuvant therapy for patients with high-risk melanoma. Efforts to modify IFN dose and schedule have not improved efficacy. We sought to determine whether a shorter course of biochemotherapy would be more effective.Patients and Methods
S0008 (S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma) was an Intergroup phase III trial that enrolled high-risk patients (stage IIIA-N2a through IIIC-N3), randomly assigning them to receive either HDI or biochemotherapy consisting of dacarbazine, cisplatin, vinblastine, interleukin-2, IFN alfa-2b (IFN-α-2b) and granulocyte colony-stimulating factor given every 21 days for three cycles. Coprimary end points were relapse-free survival (RFS) and overall survival (OS).Results
In all, 432 patients were enrolled. Grade 3 and 4 adverse events occurred in 57% and 7% of HDI patients and 36% and 40% of biochemotherapy patients, respectively. At a median follow-up of 7.2 years, biochemotherapy improved RFS (hazard ratio [HR], 0.75; 95% CI, 0.58 to 0.97; P = .015), with a median RFS of 4.0 years (95% CI, 1.9 years to not reached [NR]) versus 1.9 years for HDI (95% CI, 1.2 to 2.8 years) and a 5-year RFS of 48% versus 39%. Median OS was not different (HR, 0.98; 95% CI, 0.74 to 1.31; P = .55), with a median OS of 9.9 years (95% CI, 4.62 years to NR) for biochemotherapy versus 6.7 years (95% CI, 4.5 years to NR) for HDI and a 5-year OS of 56% for both arms.Conclusion
Biochemotherapy is a shorter, alternative adjuvant treatment for patients with high-risk melanoma that provides statistically significant improvement in RFS but no difference in OS and more toxicity compared with HDI.
Northwestern University scientists have demonstrated a genetic-based approach that is able to detect live circulating tumor cells out of the complex matrix that is human blood.
A fact sheet about research on electric and magnetic fields and studies examining their potential connection with cancer.
NCI is sponsoring two clinical trials of a monoclonal antibody called ch14.18, in combination with other drugs, to see if the antibody may be helpful for children or young adults (up to age 21) with relapsed or refractory high-risk neuroblastoma.
This article gives an overview of Partnerships to Advance Cancer Health Equity (PACHE), which involves Historically Black Colleges and Universities working in cancer disparities research.
Nation’s largest non-government, not-for-profit cancer research funder awards 83 grants totaling $44 million in second of two cycles for 2014
Rates increasing among African-Americans; reasons unclear
American Cancer Society Offers Tips to Quit During the Great American Smokeout November 20